Coronavirus BRIEFING
Supported by Essilor

The National Average for Gross Revenue at ECP Locations Increased for the Week of June 10–16, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Thursday, June 20, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations increased last week, June 10–16, when compared with the previous week, at a rate of 3 index points. That places gross revenue at a level 11 index points above where it was at this point in time (Week 24) when compared with last year (2023), 18 points above the same period in 2022, 22 points above 2021, 24 points above 2020 and 29 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

The National Average for Gross Revenue at ECP Locations Increased for the Week of June 3–9, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Thursday, June 13, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations increased last week, June 3–9, when compared with the previous week, at a rate of 23 index points. That places gross revenue at a level 30 index points above where it was at this point in time (Week 23) when compared with last year (2023), 37 points above the same period in 2022, 42 points above 2021, 25 points above 2020 and 25 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

A Combination Flu and COVID Shot

By Staff
Tuesday, June 11, 2024 10:30 AM This week, Moderna announced that its combination COVID and flu vaccine "generated even better immune responses against SARS-CoV-2 and influenza than those elicited by existing, separate vaccines," TIME reports. Head over to TIME for more on this potential combination vaccine. 

MDs' One-Word Summary of Long COVID Progress: 'Frustration'

By Staff
Tuesday, June 11, 2024 8:02 AM Stuart Malcolm, MD, a primary care physician who practices in Oregon and Northern California, started seeing patients with long COVID early in the pandemic. Back then, he was frustrated by the obstacles and lack of standard diagnostic tests and treatments. Four years later, well, he still is.

COVID Shots Should Target Variants With JN.1 Lineage in 2024-25 Campaign, U.S. FDA Advisers Say

By Staff
Monday, June 10, 2024 8:02 AM Last week, advisers to the U.S. Food and Drug Administration unanimously voted in favor of recommending that COVID-19 vaccines for 2024-25 should target a strain within the lineage of the JN.1 variant that has been dominant this year.

'Unusual' Cancers Emerge After Pandemic

By Staff
Monday, June 10, 2024 6:09 AM Some "unusual" cancers emerged during the pandemic, but is COVID to blame? The uptick in aggressive, late-stage cancers since the dawn of the pandemic is confirmed by some early national data and a number of large cancer institutions.

Paxlovid Trial Flops for COVID Pneumonia

By Staff
Friday, June 7, 2024 6:09 AM In 2021, nirmatrelvir/ritonavir clearly decreased hospitalization and death among COVID-19 patients who had high risks of severe disease and who had not been vaccinated or previously infected. It's a drug that saved lives, and would have saved many more if the vaccines had not beaten it to the punch.

FDA Advisors Give a Hearty Thumbs Up to a COVID Vaccine Based on the JN.1 Strain

By Staff
Thursday, June 6, 2024 6:09 AM An FDA advisory committee voted unanimously, 16-0, Wednesday to recommend that the COVID-19 vaccines for the 2024-2025 season target the JN.1 strain of the virus.

The National Average for Gross Revenue at ECP Locations Decreased for the Week of May 27–June 2, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Thursday, June 6, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations decreased last week, May 27–June 2, when compared with the previous week at a rate of -19 index points due to the long Memorial Day weekend. That places gross revenue at a level -11 index points below where it was at this point in time (Week 22) when compared with last year (2023), -4 points below the same period in 2022, 1 point above 2021, 27 points above 2020 and 20 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

The Push to Get More People Into Long COVID Studies

By Staff
Wednesday, June 5, 2024 8:02 AM When Ezra Spier was diagnosed with long COVID in late 2022, his main symptom, postexertional malaise, caused fatigue so severe that it forced him to quit his job as a technology entrepreneur. Since then, it's been a tough road for Spier, 37, who said he wouldn't wish his hellish condition on anyone.

Fauci Denies 'False Accusation' of COVID Origins Cover-Up

By Staff
Tuesday, June 4, 2024 6:09 AM House Republicans grilled Anthony Fauci, MD, former chief medical adviser to President Biden, during a contentious House hearing on Monday, but Fauci was adamant that accusations about his involvement in a cover-up of COVID-19's origins were false.

FDA Panel to Consider Which COVID Strain to Target in an Updated Vaccine

By Staff
Tuesday, June 4, 2024 6:09 AM The current predominant strain of COVID-19 should be a key consideration during the upcoming meeting of an FDA advisory committee tasked with making recommendations about the next COVID vaccine, agency staff said in a briefing document released Monday.

The National Average for Gross Revenue at ECP Locations Decreased for the Week of May 20–26, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Monday, June 3, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations decreased last week, May 20–26, when compared with the previous week at a rate of -2 index points. That places gross revenue at a level 6 index points above where it was at this point in time (Week 21) when compared with last year (2023), 13 points above the same period in 2022, 17 points above 2021, 37 points above 2020 (during COVID) and 25 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

COVID Shot After Acute Coronary Syndrome Might Not Prevent Further Events

By Staff
Saturday, June 1, 2024 6:09 AM Vaccination for COVID-19 after an acute coronary syndrome (ACS) event was not associated with better cardiopulmonary outcomes or fewer major adverse cardiovascular events, according to a secondary analysis of the Brazilian VIP-ACS trial.

Pandemic Reverses Global Life Expectancy Gains, WHO Reports

By Staff
Friday, May 31, 2024 8:00 AM New data from the World Health Organization (WHO) shows an alarming regression in global life expectancy. The latest edition of World Health Statistics finds that there has been a reversal in life expectancy at birth and health life expectancy at birth since the onset of the COVID-19 pandemic. 

According to the report, the pandemic wiped out nearly a decade of progress in improving life expectancy within just two years. New data shows that between 2019 and 2021, global life expectancy fell by 1.8 years to 71.4 years, a level not seen since 2012. Additionally, global healthy life expectancy dropped by 1.5 years to 61.9 years in 2021, figures also not seen since 2012.

Regions hit particularly hard were the Americas and Southeast Asia, where life expectancy fell by 3 years and healthy life expectancy dropped by 2.5 years between 2019 and 2021. Meanwhile, in the Western Pacific Region, which was minimally affected during the first two years of the pandemic, the average life expectancy fell by just 0.1 years in life expectancy and healthy life expectancy fell by 0.2 years.

Obesity also remains a significant contributor to reduced life expectancy globally. In 2022, more than one billion people aged five years and older were living with obesity, and of these, 37 million were children. 

More than half a billion people are considered underweight globally. According to the WHO, malnutrition affects 148 million children under five years old, resulting in stunting or being too short for their age, while 45 million children are suffering from wasting or being too thin for their height. 

The WHO points to the continued need for universal health coverage to help improve these numbers. In recent years, universal health coverage expanded to 585 million more people, however, this falls short of the 1 billion people goal, the WHO stated.